About this trial
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.
Age ≥18 years
LVEF >35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.
Disqualifiers
Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)
Previous CABG within the last 3 months before index hospitalization
Life expectancy less than 1 year or severe neurologic outcome
Unable or unwilling to give informed consent
Trial design
Parallel
Treatments tested in this trial
Implantable cardioverter defibrillator
DeviceImplantation of an ICD for secondary prevention
Treatment groups
Trial outcomes
Primary outcomes
All-cause mortality
The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism. Mortality will be classified as cardiovascular and non-cardiovascular.
Secondary outcomes
All cause mortality
Sudden cardiovascular death
Cardiovascular death fulfilling the following criteria: * In witnessed cases a change in cardiovascular status with time until death being \<1 hour. * In unwitnessed cases \<24 hours since last seen alive and functioning normal.
Cardiovascular death
Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes: * Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure). * Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease. * All procedure-related deaths, including those related to a complication of the ICD-procedure or treatment for a complication of the procedure. * All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events. * Death of unknown or cardiac cause.
Other outcomes
Device revision or replacement due to infection or malfunction
Explorative outcome
Appropriate shock from an ICD (successfully treated VT/VF)
Explorative outcome
Inappropriate shock from an ICD (shock on non-VT/VF)
Explorative outcome
Register-based all cause mortality
Sponsors and contacts
Click on the lead sponsor to view all of their trials.